An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
Public ClinicalTrials.gov record NCT00057239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
Study identification
- NCT ID
- NCT00057239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 546 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2003 (Type not available)
- Primary completion
- May 2004 (Actual)
- Completion
- May 2004 (Actual)
- Last update posted
- Oct 4, 2010
2003 – 2004
United States locations
- U.S. sites
- 29
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Little Rock | Arkansas | 72223 | — |
| GSK Investigational Site | Newport Beach | California | 92660-2814 | — |
| GSK Investigational Site | Farmington | Connecticut | 6708 | — |
| GSK Investigational Site | Largo | Florida | 33773 | — |
| GSK Investigational Site | Maitland | Florida | 32751 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | North Miami | Florida | 33161 | — |
| GSK Investigational Site | Edwardsville | Illinois | 62025 | — |
| GSK Investigational Site | Glen Burnie | Maryland | 21061 | — |
| GSK Investigational Site | Farmington Hills | Michigan | 48336 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55454 | — |
| GSK Investigational Site | Clementon | New Jersey | 08021 | — |
| GSK Investigational Site | Kenilworth | New Jersey | 07033 | — |
| GSK Investigational Site | Lawrence | New York | 11559 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28203 | — |
| GSK Investigational Site | Cleveland | Ohio | 44106 | — |
| GSK Investigational Site | Dayton | Ohio | 45408 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73118 | — |
| GSK Investigational Site | Eugene | Oregon | 97401 | — |
| GSK Investigational Site | Portland | Oregon | 97209 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Conshohocken | Pennsylvania | 19428 | — |
| GSK Investigational Site | Dallas | Texas | 75235 | — |
| GSK Investigational Site | Houston | Texas | 77004 | — |
| GSK Investigational Site | Irving | Texas | 75039 | — |
| GSK Investigational Site | Woodstock | Vermont | 05091 | — |
| GSK Investigational Site | Seattle | Washington | 98104 | — |
| GSK Investigational Site | Tacoma | Washington | 98499 | — |
| GSK Investigational Site | Brown Deer | Wisconsin | 53223 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00057239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2010 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00057239 live on ClinicalTrials.gov.